CO-ARROW-ELECTRONICS
9.6.2021 16:02:07 CEST | Business Wire | Press release
Global technology solutions provider Arrow Electronics (NYSE:ARW) and ROOQ, an innovator in sports measurement and analytics technology, have teamed up to create the ROOQ BOX, a sensor technology that enables boxers to monitor and review their performance using data that was previously only available under laboratory conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005194/en/
ROOQ BOX comprises a pair of sensors worn within a strap on each wrist. The sensors record the movements made during boxing activity. The data is then analyzed in the accompanying ROOQ app and cloud using machine learning algorithms to provide a precise record of the session. Using this information, boxers and trainers can create a detailed picture of the training session including punch count, punch speeds, variability and punch force. The algorithm has been trained to identify eight different types of punches and to automatically categorize these while filtering out non-boxing specific motions.
The data delivered by the sensor technology, which was inaccessible to athletes until now, provides an invaluable tool to help boxers monitor and improve their performance. This information can be shared with their coaches. In developing the system, ROOQ has drawn on a wide range of experience from within its team including data, software, hardware and firmware specialists, sports scientists and mathematicians as well as boxers and coaches. This experience reaches to the highest level: ROOQ’s chief sports officer, Henry Maske, is an Olympic boxing champion (gold medal, Seoul 1988) and professional world champion (1993 to 1996).
Arrow has been instrumental in leading the project in the firmware and hardware area between the suppliers of components, development and manufacturing services. Also, Arrow’s eInfochips engineering services were utilized in the project. Arrow has used its logistical and supply chain expertise to enable the product to be brought to market, and production scaled, in a smooth and efficient manner.
"This successful collaboration with ROOQ is a perfect example of how expert teams join forces and overcome difficult entrepreneurial challenges together," said Martin Bielesch, president of Arrow’s components business in EMEA. "Arrow's technical and logistical services enabled ROOQ to focus and execute on its leading competencies in delivering a completely new way of capturing diagnostic data in boxing."
Henry Maske sees many advantages in the cooperation between the two companies. "Arrow is a reliable and solution-oriented partner for us. We benefit from their immense experience as well as from their excellent global network.”
Boxing is just the beginning. The training diagnostics technology is universally applicable. Ralf Rüttgers, founder and CEO at ROOQ, is convinced that the application areas of ROOQ are manifold. He said, "Further development and transfer to the fitness market and other related sports, as well as use in the industrial sector, are all possible. Areas such as prevention, safety and health, will play a role in our future training analysis.”
About Arrow Electronics
Arrow Electronics guides innovation forward for over 180,000 leading technology manufacturers and service providers. With 2020 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .
About ROOQ
ROOQ is about to enter the global market with its training analysis technology. The company employs an interdisciplinary team of over 25 people at its headquarters in Aachen, Germany. The technology model founded in 2018, is a novelty for boxing. For the first time, athletes and coaches receive individualized information on their training performance. For more information, visit rooq.de.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom